Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindo’s inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.